General Counsel Karen DeHaan-Fullerton buys 104,300 shares of ZOMDF at $0.05 in initial stake purchase.
DeHaan-Fullerton, serving as General Counsel and Corporate Secretary, purchased 104,300 shares at $0.05 for $5,006.40, establishing an initial position in Zomedica. The company operates at a significant scale with $6.5M in latest quarterly revenue but is deeply unprofitable, having recorded $-63.8M in net income over its most recent fiscal year. The transaction occurs at the lower end of the stock's 52-week range ($0.03–$0.08), approximately 37.5% below the 52-week high, though the stock has gained 3.1% over the past 30 days. This initial insider purchase by a senior executive in a financially distressed but revenue-growing biotech company merits monitoring, as insider accumulation patterns and broader operational turnaround execution will be critical signals going forward.